These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 36053820)

  • 1. Improved patient-reported outcomes with iGlarLixi versus premix BIAsp 30 in people with type 2 diabetes in the SoliMix trial.
    Polonsky WH; Giorgino F; Rosenstock J; Whitmire K; Lew E; Coudert M; Alvarez A; Nicholls C; McCrimmon RJ
    Diabetes Obes Metab; 2022 Dec; 24(12):2364-2372. PubMed ID: 36053820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advancing therapy in people with suboptimally controlled basal insulin-treated type 2 diabetes: Subanalysis of the SoliMix trial in participants in Latin American countries.
    Frechtel G; Sauque-Reyna L; Choza-Romero R; Anguiano L; Melas-Melt L; Sañudo-Maury ME
    Diabetes Obes Metab; 2023 Sep; 25(9):2526-2534. PubMed ID: 37253689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advancing therapy with iGlarLixi versus premix BIAsp 30 in basal insulin-treated type 2 diabetes: Design and baseline characteristics of the SoliMix randomized controlled trial.
    McCrimmon RJ; Al Sifri S; Emral R; Mohan V; Sauque-Reyna L; Trescolí C; Lalic N; Alvarez A; Demil N; Coudert M; Shaunik A; Bonnemaire M; Rosenstock J;
    Diabetes Obes Metab; 2021 Jun; 23(6):1221-1231. PubMed ID: 33606908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoglycaemia events with iGlarLixi versus premix biphasic insulin aspart 30 (BIAsp 30) in people with type 2 diabetes advancing from basal insulin: An analysis of the SoliMix trial.
    McCrimmon RJ; Home P; Cheng A; Giorgino F; Fonseca V; Souhami E; Alvarez A; Picard P; Rosenstock J
    Diabetes Obes Metab; 2022 Dec; 24(12):2391-2399. PubMed ID: 36054624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Findings for iGlarLixi versus BIAsp 30 confirmed in groups of people with type 2 diabetes with different biomedical characteristics.
    Home PD; McCrimmon RJ; Rosenstock J; Blüher M; Pegelow K; Melas-Melt L; Djaballah K; Giorgino F;
    Diabetes Obes Metab; 2023 Mar; 25(3):656-663. PubMed ID: 36309941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advancing Therapy in Suboptimally Controlled Basal Insulin-Treated Type 2 Diabetes: Clinical Outcomes With iGlarLixi Versus Premix BIAsp 30 in the SoliMix Randomized Controlled Trial.
    Rosenstock J; Emral R; Sauque-Reyna L; Mohan V; Trescolí C; Al Sifri S; Lalic N; Alvarez A; Picard P; Bonnemaire M; Demil N; McCrimmon RJ;
    Diabetes Care; 2021 Jun; 44(10):2361-70. PubMed ID: 34183429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli-D randomized controlled trial.
    Liu M; Gu W; Chen L; Li Y; Kuang H; Du J; Alvarez A; Lauand F; Souhami E; Zhang J; Xu W; Du Q; Mu Y;
    Diabetes Obes Metab; 2024 Sep; 26(9):3791-3800. PubMed ID: 38922731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan-O-AP randomized controlled trial.
    Yang W; Dong X; Li Q; Cheng Z; Yuan G; Liu M; Xiao J; Gu S; Niemoeller E; Chen L; Ping L; Souhami E;
    Diabetes Obes Metab; 2022 Aug; 24(8):1522-1533. PubMed ID: 35441412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved glycaemic control and weight benefit with iGlarLixi versus insulin glargine 100 U/mL in Chinese people with type 2 diabetes advancing their therapy from basal insulin plus oral antihyperglycaemic drugs: Results from the LixiLan-L-CN randomized controlled trial.
    Yuan X; Guo X; Zhang J; Dong X; Lu Y; Pang W; Gu S; Niemoeller E; Ping L; Nian G; Souhami E;
    Diabetes Obes Metab; 2022 Nov; 24(11):2182-2191. PubMed ID: 35762489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in Patients with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the UK.
    McCrimmon RJ; Palmer K; Alsaleh AJO; Lew E; Puttanna A
    Diabetes Ther; 2022 Jun; 13(6):1203-1214. PubMed ID: 35543869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
    Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
    Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in People with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the US.
    Shao H; Alsaleh AJO; Dex T; Lew E; Fonseca V
    Diabetes Ther; 2022 Sep; 13(9):1659-1670. PubMed ID: 35930188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III, open-label, 2:1 randomized, treat-to-target trial.
    Yang W; Ma J; Hong T; Liu M; Miao H; Peng Y; Wang C; Xu X; Yang T; Nielsen AM; Pan L; Liu W; Zhao W
    Diabetes Obes Metab; 2019 Jul; 21(7):1652-1660. PubMed ID: 30869183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape).
    Vora J; Cohen N; Evans M; Hockey A; Speight J; Whately-Smith C
    Diabetes Obes Metab; 2015 Dec; 17(12):1133-41. PubMed ID: 26085028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching to iGlarLixi versus continuation of a daily or weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) in insufficiently controlled type 2 diabetes: A LixiLan-G trial subgroup analysis by HbA1c and GLP-1 RA use at screening.
    Rosenstock J; Blonde L; Aroda VR; Frias J; Souhami E; Ji C; Niemoeller E; Del Prato S
    Diabetes Obes Metab; 2021 Jun; 23(6):1331-1341. PubMed ID: 33565209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of biphasic insulin aspart in patients with type 2 diabetes.
    Halimi S; Raskin P; Liebl A; Kawamori R; Fulcher G; Yan G
    Clin Ther; 2005; 27 Suppl B():S57-74. PubMed ID: 16519038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world study of the concomitant use of biphasic insulin aspart 30/70 with GLP-1 receptor agonist versus first-generation basal insulin with GLP-1 receptor agonist in type 2 diabetes.
    Davies M; Alibegovic AC; Anil G; Braae UC; Jensen AB; Nordsborg RB
    Diabet Med; 2024 May; 41(5):e15267. PubMed ID: 38088483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of three-times-daily versus twice-daily biphasic insulin aspart 30 in patients with type 2 diabetes mellitus inadequately controlled with basal insulin combined with oral antidiabetic drugs.
    Yang W; Ersoy C; Wang G; Ye S; Liu J; Miao H; Asirvatham A; Werther S; Kadu P; Chow F
    Diabetes Res Clin Pract; 2019 Apr; 150():158-166. PubMed ID: 30872064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of twice-daily biphasic insulin aspart 70/30 and once-daily insulin glargine in persons with type 2 diabetes mellitus inadequately controlled on basal insulin and oral therapy: a randomized, open-label study.
    Ligthelm RJ; Gylvin T; DeLuzio T; Raskin P
    Endocr Pract; 2011; 17(1):41-50. PubMed ID: 20713345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of achieving HbA(1c) <7% and no hypoglycaemia 6 months after initiation of biphasic insulin aspart 30 in patients with type 2 diabetes in the IMPROVE study.
    Valensi P; Shaban J; Benroubi M; Kawamori R; Borzì V; Shah S; Wenying Y; Prusty V; Hansen JB; Gumprecht J;
    Curr Med Res Opin; 2013 Jun; 29(6):601-9. PubMed ID: 23488447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.